|
|
| 產(chǎn)品基本信息 |
|
| 產(chǎn)品編號(hào):P210927 |
| 產(chǎn)品名稱:Pazopanib-d3 Hydrochloride |
| 產(chǎn)品CAS: |
| 規(guī)格含量:50mg |
| 產(chǎn)品價(jià)格:面議 |
| 聯(lián)系我們: |
|
|
|
|
|
| 產(chǎn)品詳細(xì)介紹 |
| 標(biāo)準(zhǔn)品編號(hào): |
P210927 |
| 名稱: |
Pazopanib-d3 Hydrochloride |
| 別名: |
Votrient-d3 Hydrochloride; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide-d3 Hydrochloride; |
| 參考CAS號(hào): |
Unlabelled: 635702-64-6 |
| 分子式: |
C??H??D?ClN?O?S |
| 外觀: |
Light Brown Solid |
| 熔點(diǎn): |
>287°C (dec.) |
| 分子量: |
477 |
| 儲(chǔ)存: |
Hygroscopic, 冰箱, under inert atmosphere |
| 溶解度: |
DMSO (Slightly), Methanol (Slightly) |
| 類(lèi)別: |
Standards; Isotopic Labeled Analogues; Pharmaceutical/API Drug Impurities/Metabolites; |
| 應(yīng)用: |
Pazopanib-d3 is the isotope labelled analog of Pazopanib (P210925), an oral angiogenesis inhibitor targeting VEGFR and PDGFR. |
| 參考文獻(xiàn) |
|
|
|
|
|
|